ENDPOINTS

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

BioNTech has highly encouraging survival data for its bispecific antibody combining checkpoint blockade with VEGF-A inhibition as a first-line treatment for a serious form of lung cancer. And if the drug can maintain a similar ...

Mar 28, 2025 - 13:03
 0
BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer
BioNTech has highly encouraging survival data for its bispecific antibody combining checkpoint blockade with VEGF-A inhibition as a first-line treatment for a serious form of lung cancer. And if the drug can maintain a similar ...
Read More

Tags:

Previous Article

Webb Sees Neptune's Auroras for the First Time

Next Article

Don't miss the partial solar eclipse tomorrow: Where, when and how to see it

Related Posts

European regulator rejects Lilly's Alzheimer’s drug over side effects

European regulator rejects Lilly's Alzheimer’s drug ove...

Mar 28, 2025  0

AI scribes reduce burnout, but financial returns unclear — report

AI scribes reduce burnout, but financial returns unclea...

Mar 27, 2025  0

Subsense launches with $17M to build a noninvasive brain computer interface

Subsense launches with $17M to build a noninvasive brai...

Feb 18, 2025  0